In 2023-24, Indian authorities tested 106,150 drug samples, finding 2,988 substandard and 282 spurious. 604 prosecutions were launched against manufacturers and distributors. Risk-based inspections of over 500 pharmaceutical companies led to show-cause notices, production halts, and license suspensions or cancellations for non-compliance.
